Development and Validation of a Deep-Learning Model for Differential Treatment Benefit Prediction for Adults with Major Depressive Disorder Deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study
Authors:
David Benrimoh,
Caitrin Armstrong,
Joseph Mehltretter,
Robert Fratila,
Kelly Perlman,
Sonia Israel,
Adam Kapelner,
Sagar V. Parikh,
Jordan F. Karp,
Katherine Heller,
Gustavo Turecki
Abstract:
INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes, which was deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study. OBJECTIVES: 1) Develop a model capable of predicting probabilities of remiss…
▽ More
INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes, which was deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study. OBJECTIVES: 1) Develop a model capable of predicting probabilities of remission across multiple pharmacological treatments for adults with at least moderate major depression. 2) Validate model predictions and examine them for amplification of harmful biases. METHODS: Data from previous clinical trials of antidepressant medications were standardized into a common framework and included 9,042 adults with moderate to severe major depression. Feature selection retained 25 clinical and demographic variables. Using Bayesian optimization, a deep learning model was trained on the training set, refined using the validation set, and tested once on the held-out test set. RESULTS: In the evaluation on the held-out test set, the model demonstrated achieved an AUC of 0.65. The model outperformed a null model on the test set (p = 0.01). The model demonstrated clinical utility, achieving an absolute improvement in population remission rate in hypothetical and actual improvement testing. While the model did identify one drug (escitalopram) as generally outperforming the other drugs (consistent with the input data), there was otherwise significant variation in drug rankings. On bias testing, the model did not amplify potentially harmful biases. CONCLUSIONS: We demonstrate the first model capable of predicting outcomes for 10 different treatment options for patients with MDD, intended to be used at or near the start of treatment to personalize treatment. The model was put into clinical practice during the AIDME randomized controlled trial whose results are reported separately.
△ Less
Submitted 7 June, 2024;
originally announced June 2024.
Towards Outcome-Driven Patient Subgroups: A Machine Learning Analysis Across Six Depression Treatment Studies
Authors:
David Benrimoh,
Akiva Kleinerman,
Toshi A. Furukawa,
Charles F. Reynolds III,
Eric Lenze,
Jordan Karp,
Benoit Mulsant,
Caitrin Armstrong,
Joseph Mehltretter,
Robert Fratila,
Kelly Perlman,
Sonia Israel,
Myriam Tanguay-Sela,
Christina Popescu,
Grace Golden,
Sabrina Qassim,
Alexandra Anacleto,
Adam Kapelner,
Ariel Rosenfeld,
Gustavo Turecki
Abstract:
Major depressive disorder (MDD) is a heterogeneous condition; multiple underlying neurobiological substrates could be associated with treatment response variability. Understanding the sources of this variability and predicting outcomes has been elusive. Machine learning has shown promise in predicting treatment response in MDD, but one limitation has been the lack of clinical interpretability of m…
▽ More
Major depressive disorder (MDD) is a heterogeneous condition; multiple underlying neurobiological substrates could be associated with treatment response variability. Understanding the sources of this variability and predicting outcomes has been elusive. Machine learning has shown promise in predicting treatment response in MDD, but one limitation has been the lack of clinical interpretability of machine learning models. We analyzed data from six clinical trials of pharmacological treatment for depression (total n = 5438) using the Differential Prototypes Neural Network (DPNN), a neural network model that derives patient prototypes which can be used to derive treatment-relevant patient clusters while learning to generate probabilities for differential treatment response. A model classifying remission and outputting individual remission probabilities for five first-line monotherapies and three combination treatments was trained using clinical and demographic data. Model validity and clinical utility were measured based on area under the curve (AUC) and expected improvement in sample remission rate with model-guided treatment, respectively. Post-hoc analyses yielded clusters (subgroups) based on patient prototypes learned during training. Prototypes were evaluated for interpretability by assessing differences in feature distributions and treatment-specific outcomes. A 3-prototype model achieved an AUC of 0.66 and an expected absolute improvement in population remission rate compared to the sample remission rate. We identified three treatment-relevant patient clusters which were clinically interpretable. It is possible to produce novel treatment-relevant patient profiles using machine learning models; doing so may improve precision medicine for depression. Note: This model is not currently the subject of any active clinical trials and is not intended for clinical use.
△ Less
Submitted 30 March, 2023; v1 submitted 24 March, 2023;
originally announced March 2023.
